Basilea News http://www.basilea.com/ Basilea News en Sat, 16 Dec 2017 10:09:40 +0100 Sat, 16 Dec 2017 10:09:40 +0100 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific]]> http://www.basilea.com/News-and-Media/Basilea-extends-existing-license-agreement-with-Pfizer-for-antifungal-Cresemba-isavuconazole-to-China-and-Asia-Pacific/21a3f748-8dc8-defe-cc05-b38c70c058f4
  • Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales
  • Basilea updates its financial guidance for 2017 - improved result expected
  • ]]>
    Fri, 01 Dec 2017 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-extends-existing-license-agreement-with-Pfizer-for-antifungal-Cresemba-isavuconazole-to-China-and-Asia-Pacific/21a3f748-8dc8-defe-cc05-b38c70c058f4
    <![CDATA[Basilea reports on commercial progress of antifungal Cresemba® in Europe]]> http://www.basilea.com/News-and-Media/Basilea-reports-on-commercial-progress-of-antifungal-Cresemba-in-Europe/6d6e829d-026f-cda1-9591-87a3d96b19b2
  • Cresemba launched by Pfizer in Spain and is now commercially available in all Top-5 EU markets
  • Marketing authorization received for Switzerland
  • ]]>
    Thu, 02 Nov 2017 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-on-commercial-progress-of-antifungal-Cresemba-in-Europe/6d6e829d-026f-cda1-9591-87a3d96b19b2
    <![CDATA[Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor]]> http://www.basilea.com/News-and-Media/Basileas-Chief-Medical-Officer-Prof-Achim-Kaufhold-to-retire-and-Dr-Marc-Engelhardt-named-as-successor/c7e10caf-fb05-71ed-97a3-09b967951217 Tue, 31 Oct 2017 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basileas-Chief-Medical-Officer-Prof-Achim-Kaufhold-to-retire-and-Dr-Marc-Engelhardt-named-as-successor/c7e10caf-fb05-71ed-97a3-09b967951217 <![CDATA[Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea]]> http://www.basilea.com/News-and-Media/Strong-Cresemba-isavuconazole-sales-in-the-United-States-trigger-first-sales-milestone-payment-to-Basilea/97239c46-3ded-6775-5f61-fef7c8c516a7 Mon, 23 Oct 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Strong-Cresemba-isavuconazole-sales-in-the-United-States-trigger-first-sales-milestone-payment-to-Basilea/97239c46-3ded-6775-5f61-fef7c8c516a7 <![CDATA[Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.]]> http://www.basilea.com/News-and-Media/Basilea-announces-license-agreement-for-antibiotic-Zevtera-ceftobiprole-with-Shenzhen-China-Resources-Gosun-Pharmaceutical-Co-Ltd-/7d79c3fb-e455-3f09-0414-695cfae0c303 Thu, 28 Sep 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-license-agreement-for-antibiotic-Zevtera-ceftobiprole-with-Shenzhen-China-Resources-Gosun-Pharmaceutical-Co-Ltd-/7d79c3fb-e455-3f09-0414-695cfae0c303 <![CDATA[Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Cardiome-to-commercialize-antibiotic-Zevtera-Mabelio-ceftobiprole-in-Europe-and-Israel/ecceb5ae-545a-c7e4-5bff-a322d8746b62 Tue, 12 Sep 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Cardiome-to-commercialize-antibiotic-Zevtera-Mabelio-ceftobiprole-in-Europe-and-Israel/ecceb5ae-545a-c7e4-5bff-a322d8746b62 <![CDATA[Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs]]> http://www.basilea.com/News-and-Media/Basilea-reports-improved-financial-results-in-half-year-2017-driven-by-growing-product-sales-significant-progress-on-partnering-and-development-programs/08e2fba8-ea27-434f-39a7-d9e502ded357
  • Completed license agreement with Pfizer for Cresemba in Europe (excluding Nordics), Russia, Turkey and Israel; CHF 70 million upfront payment and up to USD 427 million in milestones
  • 56 percent increase in total revenue, amounting to CHF 46.2 million
  • BARDA committed USD 54.8 million in additional funding to support phase 3 development of ceftobiprole for registration in the U.S.
  • Agreement with Adult Brain Tumor Consortium for phase 1 clinical study to explore BAL101553 in newly diagnosed glioblastoma
  • ]]>
    Thu, 10 Aug 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-improved-financial-results-in-half-year-2017-driven-by-growing-product-sales-significant-progress-on-partnering-and-development-programs/08e2fba8-ea27-434f-39a7-d9e502ded357
    <![CDATA[Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel]]> http://www.basilea.com/News-and-Media/Basilea-announces-completion-of-the-license-agreement-with-Pfizer-for-antifungal-Cresemba-for-Europe-Russia-Turkey-and-Israel/884079b3-1278-5422-afa3-50f7fc66a14b Thu, 20 Jul 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-completion-of-the-license-agreement-with-Pfizer-for-antifungal-Cresemba-for-Europe-Russia-Turkey-and-Israel/884079b3-1278-5422-afa3-50f7fc66a14b <![CDATA[Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel]]> http://www.basilea.com/News-and-Media/Basilea-announces-license-agreement-with-Pfizer-for-antifungal-Cresemba-isavuconazole-for-Europe-Russia-Turkey-and-Israel/cbea2c91-3a40-52bc-ad8e-d611023188d9
  • Basilea receives a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and double-digit royalties on sales
  • Basilea continues to focus on establishing further partnerships for the commercialization of its anti-infectives Cresemba and Zevtera in key markets around the world
  • Basilea explores partnering opportunities to further strengthen its anti-infectives and oncology R&D portfolio

  • ]]>
    Wed, 14 Jun 2017 19:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-license-agreement-with-Pfizer-for-antifungal-Cresemba-isavuconazole-for-Europe-Russia-Turkey-and-Israel/cbea2c91-3a40-52bc-ad8e-d611023188d9
    <![CDATA[Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Avir-Pharma-Inc-for-Cresemba-isavuconazole-and-Zevtera-ceftobiprole-in-Canada/8bf66ebc-15c4-5087-3111-21223968aa34 Wed, 14 Jun 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Avir-Pharma-Inc-for-Cresemba-isavuconazole-and-Zevtera-ceftobiprole-in-Canada/8bf66ebc-15c4-5087-3111-21223968aa34